Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12432723 | 0.87 | KMT2A (0.60) | KDM4EALDH1A1GAAMAPTKMT2A | |
| SCHEMBL3378826 | 0.86 | MAPK1 (0.53) | KDM4EALDH1A1TDP1MAPTKMT2A | |
| SCHEMBL15417767 | 0.83 | TDP1 (0.56) | ALDH1A1TDP1POLBGAAMAPT | |
| SCHEMBL12433148 | 0.83 | DRD4 (0.55) | ALDH1A1POLBKMT2AMC4RMEN1 | |
| SCHEMBL327602 | 0.82 | KDM4E (0.49) | KDM4EALDH1A1TDP1POLBNR1H2 | |
| SCHEMBL15314567 | 0.81 | ACHE (0.62) | ALDH1A1POLBKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4758225 | 0.80 | NR1H2 (0.64) | KDM4EALDH1A1TDP1POLBNR1H2 | |
| SCHEMBL21551100 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1TDP1POLBNR1H2 | |
| SCHEMBL9926517 | 0.80 | ALDH1A1 (0.66) | KDM4EALDH1A1TDP1POLBNR1H2 | |
| SCHEMBL12139629 | 0.79 | HRH3 (0.50) | KDM4EALDH1A1TDP1POLBNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1533304-B1 | AMIDE DERIVATIVE | NIPPON SHINYAKU CO LTD (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-7494997-B2 | Amide derivative | NIPPON SHINYAKU CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| CN-100343237-C | Amide derivative and medicine | NIPPON SHINYAKU CO LTD (JP) | 2007-10-17 | — | — | CN | disclosed |
| US-20060014742-A1 | Amide derivative | NIPPON SHINYAKU CO., LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| CN-1678590-A | Amide derivative and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 2005-10-05 | — | — | CN | disclosed |
| EP-1533304-A1 | AMIDE DERIVATIVE | Nippon Shinyaku Co., Ltd. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014742-A1 | Amide derivative | ABL1, ABL2, BCR | KDM4E 1606/4885ALDH1A1 753/4885TDP1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.